A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Clinical trial NCT05207670 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05207670
- Sponsor
- Genentech, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-01
- Primary completion
- 2027-07-31
- Enrollment
- 320
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.